Skip to content
etf.net

BIB vs UYG

ProShares Ultra Nasdaq Biotechnology

BIBBNasdaq

ProShares Ultra Financials

UYGANYSE Arca

Overlap

Expense ratio

UYG −0.02pt a year

BIB0.95%UYG0.93%

Avg volume · 30D

UYG 1.6×the volume

BIB10.5KUYG17.3K

10Y return · a year

UYG +4.4pt

BIB+12.6%UYG+17.0%

BIB vs UYG Performance

Oct 29, 2021 – Oct 30, 2026

+36.3%BIB+56.5%UYG

Oct 29, 2021 to Oct 30, 2026. BIB +36.3%. UYG +56.5%. Use the arrow keys to read each point.−50%−25%0%75%Oct 2021Apr 2024Oct 2026
Expense ratio
BIB 0.95%
UYG 0.93%, better
Fund size
BIB $104M
UYG $777M
1Y total return
BIB +68.9%, better
UYG +11.5%
Yield (12M)
BIB 0.19%
UYG 11.13%, better
Holdings
BIB 247
UYG 83
Avg volume (30D)
BIB 10.5K sh
UYG 17.3K sh, better
NAV per share
BIB $120.62
UYG $93.27
52W range

ETF.net Grade

BIB: Cost 51, Risk 70, Mission not scored, Tradability 84, Holdings 60, Durability 75. UYG: Cost 70, Risk 76, Mission not scored, Tradability 78, Holdings not scored, Durability 80.
Pillar letters and Scores for BIB, UYG, with each pillar’s weight
PillarBIBUYG
Cost30% weightC51A70Higher
Mission25% weightNot scoredNot scored
Risk15% weightA70A76Higher
Tradability15% weightA84HigherA78
Holdings10% weightB60Not scored
Durability5% weightA75A80Higher

Rank among Leveraged Long (2x & Other) funds

How we build Categories ›
Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

Same Category. BIB and UYG are both graded against the same 95 Leveraged Long (2x & Other) funds, so their Grades compare head to head.

Leveraged Long (2x & Other)⁠

Category · 95 funds
See all 95 ›

UYG ranks 2nd and BIB 8th of 95 funds in the Leveraged Long (2x & Other) Category.

  1. Rank 1AQLDProShares Ultra QQQScore 77
  2. Rank 2AUYGProShares Ultra FinancialsScore 74
  3. Rank 3AROMProShares Ultra TechnologyScore 71
  4. Rank 7BUJBProShares Ultra High YieldScore 65
  5. Rank 8BBIBProShares Ultra Nasdaq BiotechnologyScore 64
  6. Rank 9BMVVProShares Ultra MidCap400Score 63

Our read on each fund

ETF.net Research

BIBBProShares Ultra Nasdaq Biotechnology

UYGAProShares Ultra Financials

In short

BIB Biotech with the dial at 2x, not 3x. Since 2010 BIB has aimed at twice the daily move of the Nasdaq Biotechnology Index, a modified cap-weighted set of Nasdaq-listed biotech and pharma names, reset fresh every single day.

UYG Listed in January 2007, a year before the banking crash, UYG targets 2x the daily move of the financial stocks in the S&P 500. A veteran of the leveraged shelf, priced at 0.93% with no fee waiver propping that number up.

Stated mandate

BIB The Fund seeks daily investment results, before fees and expenses, that correspond to two times the daily performance of the Nasdaq Biotechnology Index.

UYG UYG seeks pre-expense daily results equal to 2x the daily performance of the S&P Financial Select Sector Index. It is designed to provide magnified financials-sector exposure on a daily basis.

Why people hold it

  • BIB Aims for two times the daily move of the Nasdaq Biotechnology Index. Magnified biotech exposure through one ticker in a regular brokerage account, no margin agreement needed.proshares.com
  • The benchmark dates to 1993: Nasdaq-listed biotech and pharma, modified cap-weighted, roughly 300 stocks. Industry-wide exposure, not a handful of lottery tickets.nasdaqomx.comnasdaqomx.com 2
  • 0.95% net of a waiver through September 30, 2027, against a 1.17% gross. Near the category median and level with ProShares stablemate DDM at 0.95%.
  • Live since 2010 through several biotech boom-and-bust cycles, and it stands among the stronger implementations in a crowded leveraged-bull field.
  • UYG One of the originals: on the tape since January 30, 2007, still running the same mandate of 2x the daily performance of the S&P Financial Select Sector Index.proshares.com
  • At 0.93% with no waiver doing the work, it sits near the median fee of its leveraged peer group and level with sibling ROM (0.93%). QLD is 0.89%, but net of a waiver through September 30, 2027.
  • The whole sector in one ticker: banks, insurers and capital-markets firms from the S&P 500, roughly 80 names, geared daily.proshares.com
  • Stands in the top tier of the leveraged bull funds we grade, a group of close to a hundred tickers.

Worth knowing

  • BIB Daily reset. Hold past one day and compounding takes over: returns can differ in amount, and even direction, from 2x the index over that stretch.proshares.com
  • One industry, doubled. Trial readouts and FDA decisions move biotech hard, and this fund is built to amplify those days in both directions.proshares.com
  • Among the lighter-traded, smaller funds in its category, so spreads and order size matter more here than with the headline leveraged names.
  • UYG The 2x target is a one-day target and resets each day. Over longer holds the result comes from compounding daily moves, and in choppy markets that can land well off twice the index's return for the period.proshares.com
  • One sector, doubled. Financials move with rates, credit conditions and deal flow, and UYG amplifies that daily swing in both directions.
  • It changes hands less than the headline leveraged funds, so the spread is worth a look before you place an order.

Full BIB profile⁠

Full UYG profile⁠

BIB vs UYG Holdings

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

BIB vs UYG Cost

Overpaying BIB vs UYG

$330

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BIB 0.95%

    $17,869

  • UYG 0.93%

    $17,539

$10,000
30 years

Cost over time

  • BIB 0.95%
  • UYG 0.93%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$5K$10K$15K$20K051015202530BIB $17,869UYG $17,539

Year by year

YearBIBUYGOverpaying
10$1,678$1,644$34
20$6,322$6,199$123
30$17,869$17,539$330

Expense ratio

  • 0.95%BIB
  • 0.93%UYG, cheaper
  • Middle half of Leveraged Long (2x & Other) funds
  • Median 0.95%

UYG 29th cheapest of 95 funds

BIB 32nd cheapest of 95 funds

BIB vs UYG Dividends

Last 12 months to Oct 30, 2026
Yield (12M)
BIB 0.19%
UYG 11.13%, better
Payout (12M)
BIB $0.22
UYG $10.38
Last payment
BIB $0.08
UYG $0.09
Ex-dividend
BIB Sep 23, 2026
UYG Sep 23, 2026
Paid on
BIB Sep 29, 2026
UYG Sep 29, 2026
Frequency
BIB Twice a year
UYG Quarterly

Distribution history

Per share, 2017 to 2026, same scale for both

BIBTwice a year · 12 paymentsAll BIB payments⁠
One bar per payment. 12 payments from 2017 to 2026 YTD. Dec 22, 2022 $0.02; Dec 20, 2023 $0.04; Mar 20, 2024 $0.04; Jun 26, 2024 $0.26; Sep 25, 2024 $0.15; Dec 23, 2024 $0.40; Mar 26, 2025 $0.13; Jun 25, 2025 $0.17; Sep 24, 2025 $0.18; Dec 24, 2025 $0.13; Mar 25, 2026 $0.0071; Sep 23, 2026 $0.08. Use the arrow keys to read each point.$0$102017202020232026YTD
UYGQuarterly · 39 paymentsAll UYG payments⁠
One bar per payment. 39 payments from 2017 to 2026 YTD. Mar 22, 2017 $0.02; Jun 21, 2017 $0.02; Sep 27, 2017 $0.07; Dec 26, 2017 $0.12; Mar 21, 2018 $0.05; Jun 20, 2018 $0.08; Sep 26, 2018 $0.11; Dec 26, 2018 $0.18; Mar 20, 2019 $0.08; Jun 25, 2019 $0.09; Sep 25, 2019 $0.14; Dec 24, 2019 $0.17; Mar 25, 2020 $0.12; Jun 24, 2020 $0.05; Sep 23, 2020 $0.03; Dec 23, 2020 $0.08; Mar 23, 2021 $0.03; Jun 22, 2021 $0.02; Sep 22, 2021 $0.03; Dec 23, 2021 $3.19; Mar 23, 2022 $0.04; Jun 22, 2022 $0.04; Sep 21, 2022 $0.06; Dec 22, 2022 $0.20; Mar 22, 2023 $0.09; Jun 21, 2023 $0.11; Sep 20, 2023 $0.09; Dec 20, 2023 $0.15; Mar 20, 2024 $0.04; Jun 26, 2024 $0.11; Sep 25, 2024 $0.09; Dec 23, 2024 $0.20; Mar 26, 2025 $0.27; Jun 25, 2025 $0.13; Sep 24, 2025 $0.38; Dec 24, 2025 $9.97; Mar 25, 2026 $0.20; Jun 24, 2026 $0.11; Sep 23, 2026 $0.09. Use the arrow keys to read each point.$0$102017202020232026YTD

BIB vs UYG Risk

Fall from peak · 5 years

  • BIB
  • UYG
Oct 29, 2021 to Oct 30, 2026. Worst fall: BIB −61.8% · Apr 2025. Use the arrow keys to read each point.−60%−40%−20%0%Oct 2021Apr 2024Oct 2026

Risk facts

VolatilityStd dev, 3 years
BIB 33.9%UYG 30.5%, better
Return per unit of riskSharpe ratio, 3 years
BIB 1.12, betterUYG 1.04
Worst fallMax drawdown, 5 years
BIB −61.8%UYG −47.8%, better
Market sensitivityBeta, 5 years
BIB 1.20UYG 1.58

Popular comparisons

  • BIBBvsQLDA

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra QQQ

    Expense ratio
    0.95% · 0.89%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • UYGAvsQLDA

    ProShares Ultra Financials · ProShares Ultra QQQ

    Expense ratio
    0.93% · 0.89%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BIBBvsROMA

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra Technology

    Expense ratio
    0.95% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • UYGAvsROMA

    ProShares Ultra Financials · ProShares Ultra Technology

    Expense ratio
    0.93% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BIBBvsDDMB

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra Dow30

    Expense ratio
    0.95% · 0.95%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • UYGAvsDDMB

    ProShares Ultra Financials · ProShares Ultra Dow30

    Expense ratio
    0.93% · 0.95%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.